Association of mast cells and bone marrow reticulin fibrosis in patients with bcr-abl negative chronic myeloproliferative neoplasms

被引:2
|
作者
Keski, Hakan [1 ]
机构
[1] Kocaeli Univ, Dept Internal Med, Div Hematol, Kocaeli, Turkey
关键词
Bone marrow fibrosis; CD34; Mast cell; Myeloproliferative neoplasm; Reticulin fiber; PERIPHERAL-BLOOD; ESSENTIAL THROMBOCYTHEMIA; EUROPEAN CONSENSUS; CD34(+) CELLS; MYELOFIBROSIS; NUMBER; CLASSIFICATION; MASTOCYTOSIS; PROGNOSIS; IMPACT;
D O I
10.1016/j.bcmd.2020.102420
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: We aimed to investigate the association of bone marrow mast cell numbers (MCN) and the degree of reticulin fibrosis in patients with chronic myeloproliferative neoplasms (MPN). Methods: This was a case-control study that recruited 47 patients who were diagnosed with bcr-abl negative MPN. Thirty patients with lymphoma served as controls. JAK2 mutation was studied and all subjects underwent bone marrow biopsy at the time of diagnosis. Mast and CD34 + cells were counted. Marrow reticulin fiber was graded. Results: Thirty-four patients had essential thrombocythemia (ET), 8 patients had primary myelofibrosis (PMF) and 5 patients had polycythemia vera (PV). Fourteen MPN patients had JAK2, whereas the controls had not. MCN was higher in patients than controls (p = 0.001). There was no significant difference regarding CD34. Reticulin fibrosis was present in 57.4% of MPN patients, whereas there was any in controls. PMF patients had more CD34 + cells than PV and ET. PMF patients had more reticulin fibers compared with other subgroups (p < 0.001). MCN, but not CD34 + cell counts, was significantly higher in JAK2( + ) patients than JAK2( - ) patients. Conclusion: MCN and reticulin fibrosis were significantly increased in MPN patients. JAK2 positivity had significantly increased MCN compared to patients without JAK2. JAK2 was associated with increased reticulin fibrosis.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Mutation and Lineage Analysis of DNMT3A in BCR-ABL1-negative Chronic Myeloproliferative Neoplasms
    Lin, Huan-Chau
    Wang, Shu-Ching
    Chen, Caleb Gon-Shen
    Chang, Ming-Chih
    Wang, Wei-Ting
    Su, Nai-Wen
    Cheng, Hung-I
    Lin, Johnson
    Chang, Yi-Fang
    Hsieh, Ruey-Kuen
    Chang, Chien-Chung
    Hwang, Yuchi
    Lim, Ken-Hong
    Kuo, Yuan-Yeh
    INTERNATIONAL JOURNAL OF GERONTOLOGY, 2013, 7 (03) : 186 - 188
  • [32] Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives
    Ivan Krecak
    Srdan Verstovsek
    Marko Lucijanic
    Annals of Hematology, 2024, 103 : 1513 - 1523
  • [33] Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms
    Kim, Jinyong
    Byun, Ja Min
    Hong, Junshik
    Koh, Youngil
    Shin, Dong-Yeop
    Kim, Inho
    Yoon, Sung-Soo
    Park, Hyunkyung
    Bang, Soo-Mee
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [34] The Prevalence of TET2 Gene Mutations in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms (MPN): A Systematic Review and Meta-Analysis
    Chia, Yuh Cai
    Islam, Md Asiful
    Hider, Phil
    Woon, Peng Yeong
    Johan, Muhammad Farid
    Hassan, Rosline
    Ramli, Marini
    CANCERS, 2021, 13 (12)
  • [35] Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis
    Benedetta Rambaldi
    Elisa Diral
    Samantha Donsante
    Noemi Di Marzo
    Federica Mottadelli
    Lucia Cardinale
    Erica Dander
    Giuseppe Isimbaldi
    Pietro Pioltelli
    Andrea Biondi
    Mara Riminucci
    Giovanna D’Amico
    Elena Maria Elli
    Alice Pievani
    Marta Serafini
    Annals of Hematology, 2021, 100 : 105 - 116
  • [36] Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms
    J Wang
    T Ishii
    W Zhang
    S Sozer
    Y Dai
    J Mascarenhas
    V Najfeld
    Z J Zhao
    R Hoffman
    N Wisch
    M Xu
    Leukemia, 2009, 23 : 1577 - 1586
  • [37] Inhibition of proinflammatory signaling impairs fibrosis of bone marrow mesenchymal stromal cells in myeloproliferative neoplasms
    Vukotic, Milica
    Kapor, Suncica
    Dragojevic, Teodora
    Dikic, Dragoslava
    Ajtic, Olivera Mitrovic
    Diklic, Milos
    Suboticki, Tijana
    Zivkovic, Emilija
    Cokic, Bojana Beleslin
    Vojvodic, Aleksandar
    Santibanez, Juan F.
    Gotic, Mirjana
    Cokic, Vladan P.
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2022, 54 (03): : 273 - 284
  • [38] Bone marrow findings post allogeneic transplant for myeloproliferative neoplasms and chronic myelomonocytic leukemia with increased fibrosis
    Gupta, Srishti
    Courville, Elizabeth L.
    LABORATORY MEDICINE, 2024, 55 (05) : 602 - 608
  • [39] CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms
    Jorgelina Ojeda, Mara
    Margarita Bragos, Irma
    Lucrecia Calvo, Karina
    Marcela Williams, Gladis
    Magdalena Carbonell, Maria
    Flavia Pratti, Arianna
    HEMATOLOGY, 2018, 23 (04) : 208 - 211
  • [40] The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms
    Lin, Yani
    Liu, Enbin
    Sun, Qi
    Ma, Jiao
    Li, QingHua
    Cao, Zeng
    Wang, Jun
    Jia, Yujiao
    Zhang, Hongju
    Song, Zhen
    Ai, Xiaofei
    Shi, Lihui
    Feng, Xiaofang
    Li, Chenwei
    Wang, Jianxiang
    Ru, Kun
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2015, 144 (01) : 165 - 171